{
    "nctId": "NCT03579979",
    "briefTitle": "Sentinel Lymph Node Biopsy in Breast Cancer Surgery Using ICG",
    "officialTitle": "To Evaluate the Safety and Efficacy of Near-infarred Fluorescence Molecular Imaging in the Prospective, Multi-center and Self-controlled Clinical Trial of Sentinel Lymph Node Biopsy in Breast Cancer Surgery",
    "overallStatus": "COMPLETED",
    "conditions": "Sentinel Lymph Node, Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 130,
    "primaryOutcomeMeasure": "Sentinel lymph node detection number",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. the age of 18-75 years, female patients;\n2. the diagnosis of breast cancer by biopsy;\n3. participants voluntarily participated in the clinical trial and signed informed consent.\n\nExclusion Criteria:\n\n1. had received SLNB or axillary surgery;\n2. breast area radiotherapy or neoadjuvant chemotherapy has been accepted.\n3. clinical hints of axillary lymph node metastasis;\n4. discovery of distant metastasis;\n5. inflammatory breast cancer;\n6. women in pregnancy;\n7. people with iodine allergy;\n8. the serum creatinine was \\> 1.5 times as high as the upper limit of the normal value.\n9. to participate in clinical trials of other devices or drugs within one month;\n10. the researchers consider it inappropriate to participate in this clinical trial.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}